Q4 2025 earnings call: ivonescimab Phase III updates, FDA PDUFA timeline, interim PFS in Q2 2026, cash position—read now.
6 Health and Social Research Center, Universidad de Castilla La-Mancha, Cuenca, Spain Objective To examine the predictive validity of field-based muscular strength tests in relation to incident ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourth quarter and ...
BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma Early-phase clinical trials (EPCTs) have been ...
Background We describe the occurrence of second primary lung cancers (SPLCs) and their determinant in Sweden. Methods Nation-wide cancer registry from years 1961 to 2021 identified a total of 853 ...
A new analysis from the 2015 Pelotas Birth Cohort suggests that dietary patterns at just 2 years of age are associated with ...
Objective Unplanned hospital readmissions within 30 days of discharge measure the quality of healthcare. This study aims to ...
Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results